Radiation induced lymphopenia – a possible critical factor in current oncological treatment

Česká verzia

Authors: J. Kubeš; K. Dědečková; F. Al-Hamami S. Abass; V. Vondráček
Authors place of work: Proton Therapy Center Czech s. r. o.
Published in the journal: Klin Onkol 2023; 36(1): 6-11
Category: Přehled
doi: https://doi.org/10.48095/ccko20236

Summary

Background: The effect of ionizing radiation on the immune system during the treatment of malignant tumors has long remained a point of great interest. This issue is currently gaining importance, especially in connection with the advancing development and availability of immunotherapeutic treatment. During cancer treatment, radiotherapy has the ability to influence the immunogenicity of the tumor by increasing the expression of certain tumor-specific antigens. These antigens can be processed by the immune system, stimulating the transformation of naïve lymphocytes into tumor-specific lymphocytes. However, at the same time, the lymphocyte population is extremely sensitive to even low doses of ionizing radiation, and radiotherapy often induces severe lymphopenia. Severe lymphopenia is a negative prognostic factor for numerous cancer diagnoses and negatively impacts the effectiveness of immunotherapeutic treatment. Aim: In this article, we summarize the possible influence of radiotherapy on the immune system, with a particular emphasis on the impact of radiation on circulating immune cells and the subsequent consequences of this influence on the development of cancer. Conclusion: Lymphopenia is an important factor influencing the results of oncological treatment, with a common occurrence during radiotherapy. Strategies to reduce the risk of lymphopenia consist of accelerating treatment regimens, reducing target volumes, shortening the beam-on time of irradiators, optimizing radiotherapy for new critical organs, using particle radiotherapy, and other procedures that reduce the integral dose of radiation.

Keywords:

Lymphocytes – radiosensitivity – radiation-induced lymphopenia – antitumor immune response – stereotactic radiotherapy – particle radiotherapy

Zdroje

1. Syn NL, Teng MWL, Mok TSK et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 2017; 18 (12): e731–e741. doi: 10.1016/S1470-2045 (17) 30607-1.

2. Piccirillo CA. Regulatory T cells in health and disease. Cytokine 2008; 43 (3): 395–401. doi: 10.1016/j.cyto.2008.07.469.

3. Burnette B, Fu YX, Weichselbaum RR. The confluence of radiotherapy and immunotherapy. Front Oncol 2012; 2: 143. doi: 10.3389/fonc.2012.00143.

4. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203 (5): 1259–1271. doi: 10.1084/jem.20052494.

5. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13 (9): 1050–1059. doi: 10.1038/nm1622.

6. Barcellos-Hoff MH, Derynck R, Tsang ML et al. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994; 93 (2): 892–899. doi: 10.1172/JCI117045.

7. Schrek R. Qualitative and quantitative reactions of lymphocytes to x rays. Ann N Y Acad Sci 1961; 95: 839–848. doi: 10.1111/j.1749-6632.1961.tb50080.x.

8. Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res 1990; 123 (2): 224–227.

9. Hall EJ, Giaccia AJ. Radiobiology for radiologist. Lippincott Williams & Wilkins 2015.

10. Hoskin P, Popova B, Schofield O et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol 2021; 22 (3): 332–340. doi: 10.1016/S1470-2045 (20) 30686-0.

11. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105 (4): 256–265. doi: 10.1093/jnci/djs629.

12. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953; 26 (305): 234–241. doi: 10.1259/0007-1285-26-305-234.

13. Demaria S, Bhardwaj N, McBride WH et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63 (3): 655–666. doi: 10.1016/j.ijrobp.2005.06.032.

14. Park SS, Dong H, Liu X et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015; 3 (6): 610–619. doi: 10.1158/2326-6066.CIR-14-0138.

15. Vanpouille-Box C, Diamond JM, Pilones KA et al. TGFb is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 2015; 75 (11): 2232–2242. doi: 10.1158/0008-5472.CAN-14-3511.

16. Roger A, Finet A, Boru B et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. Oncoimmunology 2018; 7 (7): e1442166. doi: 10.1080/2162402X.2018.1442166.

17. Formenti SC, Lee P, Adams S et al. Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer. Clin Cancer Res 2018; 24 (11): 2493–2504. doi: 10.1158/1078-0432.CCR-17-3322.

18. Rodriguez-Ruiz ME, Perez-Gracia JL, Rodriguez I et al. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann Oncol 2018; 29 (5): 1312–1319. doi: 10.1093/annonc/mdy089.

19. Chen D, Verma V, Patel RR et al. Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1/2 trials. Int J Radiat Oncol Biol Phys 2020; 108 (1): 196–203. doi: 10.1016/j.ijrobp.2020.01.032.

20. Morisada M, Moore EC, Hodge R et al. Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncol 2017; 71: 87–94. doi: 10.1016/j.oraloncology.2017.06.005.

21. Venkatesulu BP, Mallick S, Lin SH et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol 2018; 123: 42–51. doi: 10.1016/j.critrevonc.2018.01.003.

22. Talebian Yazdi M, Schinkelshoek MS, Loof NM et al. Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer. Oncoimmunology 2016; 5 (12): e1255393. doi: 10.10 80/2162402X.2016.1255393.

23. Lambin P, Lieverse RIY, Eckert F et al. Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy. Semin Radiat Oncol 2020; 30 (2): 187–193. doi: 10.1016/j.semradonc.2019.12.003.

24. Cai S, Fan Y, Guo Q et al. Impact of radiation dose to circulating immune cells on tumor control and survival in esophageal cancer. Cancer Biother Radiopharm 2021 [ahead of print]. doi: 10.1089/cbr.2021.0250.

25. Wild AT, Yovino S, Smith JA et al. Degree of chemoradiation-associated lymphophenia is related to radiation field size in patients with locally advanced pancreatic cancer. Annu Meeting Am Radium Soc 2012.

26. Yang L, Xu Z, Ma L et al. Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer. Cancer Biomark 2022; 34 (1): 149–159. doi: 10.3233/CBM-210292.

27. Wang Q, Qiu Q, Zhang Z et al. Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy. Cancer Med 2021; 10 (17): 5847–5858. doi: 10.1002/cam4.4131.

28. Arcadipane F, Silvetti P, Olivero F et al. Bone marrow--sparing IMRT in anal cancer patients undergoing concurrent chemo-radiation: results of the first phase of a prospective phase II trial. Cancers (Basel) 2020; 12 (11): 3306. doi: 10.3390/cancers12113306.

29. Yu H, Chen F, Lam KO et al. Potential determinants for radiation-induced lymphopenia in patients with breast cancer using interpretable machine learning approach. Front Immunol 2022; 13: 768811. doi: 10.3389/fimmu.2022.768811.

30. Yovino S, Kleinberg L, Grossman SA et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 2013; 31 (2): 140–144. doi: 10.3109/07357907.2012.762780.

31. Zhao Q, Li T, Du S et al. Shortened radiation time promotes recovery from radiation-induced lymphopenia in early-stage non-small cell lung cancer patients treated with stereotactic body radiation therapy. Technol Cancer Res Treat 2022; 21: 15330338221112287. doi: 10.1177/15330338221112287.

32. Crocenzi T, Cottam B, Newell P et al. A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer 2016; 4: 45. doi: 10.1186/s40425-016-0149-6.

33. Chen D, Patel RR, Verma V et al. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol 2020; 150: 114–120. doi: 10.1016/j.radonc.2020.05.051.

34. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 2007; 108 (1): 45–51. doi: 10.1016/j.imlet.2006.10.009.

35. Chadha AS, Liu G, Chen H-C et al. Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy? Int J Radiat Oncol Biol Phys 2017; 97 (2): 323–332. doi: 10.1016/j.ijrobp.2016.10.046.

36. Damen PJJ, Kroese TE, van Hillegersberg R et al. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2021; 111 (4): 936–948. doi: 10.1016/j.ijrobp.2021.07.1695.

37. Dai D, Tian Q, Shui Y et al. The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: a systematic review and meta-analysis. Radiother Oncol 2022; 168: 28–36. doi: 10.1016/j.radonc.2022.01.003.

38. Upadhyay R, Venkatesulu BP, Giridhar P et al. Risk and impact of radiation related lymphopenia in lung cancer: a systematic review and meta-analysis. Radiother Oncol 2021; 157: 225–233. doi: 10.1016/j.radonc.2021.01.034.

39. Zhang Y, Chen S, Chen H et al. Prognostic value and risk factors of treatment-related lymphopenia in malignant glioma patients treated with chemoradiotherapy: a systematic review and meta-analysis. Front Neurol 2022; 12: 726561. doi: 10.3389/fneur.2021.726561.

40. Park JC, Durbeck J, Clark JR. Predictive value of peripheral lymphocyte counts for immne checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma. Mol Clin Oncol 2020; 13 (6): 87. doi: 10.3892/mco.2020.2157.

41. Tanizaki J, Haratani K, Hayashi H et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol 2018; 13 (1): 97–105. doi: 10.1016/j.jtho.2017.10.030.

42. Diehl A, Yarchoan M, Hopkins A et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 2017; 8 (69): 114268–114280. doi: 10.18632/oncotarget.23 217.

43. Yin T, Wang P, Yu J et al. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma. Int Immunopharmacol 2022; 106: 108623. doi: 10.1016/j.intimp.2022.108623.

44. Jing W, Xu T, Wu L et al. Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC. JTO Clin Res Rep 2022; 3 (9): 100391. doi: 10.1016/j.jtocrr.2022.100391.

45. Ladbury CJ, Rusthoven CG, Camidge DR et al. Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 2019; 105 (2): 346–355. doi: 10.1016/j.ijrobp.2019.05.064.

46. Sun GY, Wang SL, Song YW et al. Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy. Int J Radiat Oncol Biol Phys 2020; 108 (1): 277–285. doi: 10.1016/j.ijrobp.2020.02.633.

47. Filatenkov A, Baker J, Mueller AM et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 2015; 21 (16): 3727–3739. doi: 10.1158/1078-0432.CCR-14-2824.

48. Verbrugge I, Hagekyriakou J, Sharp LL et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72 (13): 3163–3174. doi: 10.1158/0008-5472.CAN-12-0210.

49. Zhao Q, Li T, Du S et al. Shortened radiation time promotes recovery from radiation-induced lymphopenia in early-stage non-small cell lung cancer patients treated with stereotactic body radiation therapy. Technol Cancer Res Treat 2022; 21: 15330338221112287. doi: 10.1177/15330338221112287.

50. So TH, Chan SK, Chan WL et al. Lymphopenia and radiation dose to circulating lymphocyte with neoadjuvant chemoradiation in esophageal squamous cell carcinoma. Adv Radiat Oncol 2020; 5 (5): 880–888. doi: 10.1016/j.adro.2020.03.021.

51. Xu C, Jin J-Y, Zhang M et al. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol 2020; 146: 180–186. doi: 10.1016/j.radonc.2020.02.015.